Assertio Holdings (ASRT)

Executive Summary

Assertio Holdings (NASDAQ: ASRT) is a commercial-stage pharmaceutical company focused on acquiring, licensing, and marketing specialty products in neurology, pain management, and hospital-based care. With a portfolio of seven commercial products, the company employs a targeted strategy to maximize value from established, non-promoted brands. Its pipeline currently includes one terminated Phase 2 candidate for migraine (Ketorolac + Prochlorperazine + Diphenhydramine), highlighting reliance on commercial execution and business development for growth. The company operates as a public entity with a market capitalization of approximately $152 million, emphasizing financial discipline and selective acquisitions within its core therapeutic areas. While near-term catalysts are limited, management's track record and focus on cost-containment provide a foundation for sustained operations.

Upcoming Catalysts (preview)

• TBDAcquisition or Licensing of New Product30% success
• Q3 2026Q3 2026 Earnings Report100% success
• TBDLabel Expansion or New Indication for Existing Product20% success